Whether anti-TFPI antibody should be used in patients with hemophilia C is debated largely because of the infrequent need for replacement products; however, their availability is important and may also play a role in the development of factor XI inhibitors for a variety of clinical indications. The gene discussed is TFPI; the disease is congenital factor XI deficiency.